Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01539174
Recruitment Status : Withdrawn (No Funding Source and Competing Trials)
First Posted : February 27, 2012
Last Update Posted : March 3, 2016
Genentech, Inc.
Information provided by (Responsible Party):
Fox Chase Cancer Center

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
  Recruitment Status : Withdrawn
  Primary Completion Date : No date given
  Study Completion Date : No date given